股票 
板块 
用户 
资讯 上市七年，美迪西穿越生物医药行业周期起伏，也在中国创新药加速前行中持续沉淀。七年来，从客户选择到行业认可，从技术攻坚到合规交付，每一份荣誉都不是孤立的标签，而是对美迪西一站式临床前服务能力的长期印证。站在上市七周年的新节点，回望来路，美迪西凭什么持续赢得行业与客户的信赖，成为众多药企坚定同行的创新伙伴？
客户之选
以交付赢得信任，以共赢成就彼此
对CRO而言，客户信任是最珍贵的褒奖。美迪西深耕药物发现、药学研究、临床前研究、注册申报等一站式临床前服务，持续为国内外创新药企提供稳定、专业、高效的研发支持。
01
从Target到IND，一站赋能新药研发
依托一站式临床前研发服务平台，美迪西打通了从Target到IND的全链路：各模块无缝衔接、数据高效互通，既避免了多供应商对接带来的沟通壁垒与数据断层，也能支持全球多报。截至目前，美迪西已累计支持43个全套IND Package项目获批临床。包括纳安生物ADC药物T320成功实现中、美、澳三报三批，标新生物GT919、GT929、GT818三款降解剂管线均实现中美双报双批，上海谊众YXC-001、YXC-002获批临床，授予美迪西药学及临床前团队“卓越合作伙伴奖”；宝太生物BIOT-006、韦恩生物WBD156、、宇耀生物YY201片、海擘生物NC527-X等项目，也均依托美迪西一站式临床前服务平台，实现中美双报双批。
02
高效履约，抢跑关键研发节点
面对新药项目紧迫的时间窗口，美迪西团队灵活调度人力、资源，以极强的执行力保障节点落地。RayThera授予卓越合作伙伴奖，表彰FTE专项团队节假日不间断攻坚、压缩项目周期提前完成研发任务；艾森药业致信点赞多部门联动作战，在全球首创双靶点新冠口服药奥格特韦钠应急研发中同步推进工艺放大、毒理样品制备与药代研究，为药物快速推进抢下宝贵时间。
03
攻坚克难，突破前沿技术瓶颈
针对前沿靶点、全新分子类型缺少成熟参考方案的行业痛点，美迪西团队自主优化实验方案、搭建专属评价体系。领泰生物授予DMPK团队专项奖，表彰其破解PROTAC分子量大、成药性评价难的痛点；艾美斐授予药效团队最佳合作伙伴奖，肯定其MCAO建模方案，为全球首个进入临床的CCR小分子拮抗剂IPG7236提供扎实支撑；核新生物授予CMC团队杰出合作伙伴奖，表彰其攻克XY003溶解度极低、制剂工艺复杂的难题；天士力致谢团队搭建PBC专项评价体系，高质量完成TSL2402片药效研究。
04
全球协同，共筑长期发展共同体
美迪西与合作伙伴的关系，正从单一项目交付走向管线协同与长期共生。国内已服务恒瑞医药、扬子江药业、白云山制药、上海医药、丽珠医药、华润医药、石药集团、华东医药等药企，荣获济民可信 “优秀业绩奖”、上海齐鲁锐格 “最佳合作伙伴” 奖、璧辰医药 “最佳服务团队” 奖、德睿医药 “优秀团队奖”、思合基因 “最佳合作伙伴奖”、京新药业 “突出贡献团队奖”、康蒂尼药业 “毒理先锋” 奖等。其中，美迪西与恒瑞医药合作15年，覆盖小核酸、抗体、多肽、ADC、PROTAC 等多种分子类型；在ADC领域，为宜联生物YL201、YL202项目提供临床前研发服务，并参与TMALIN平台有效载荷研发，获评 “最佳合作奖”。
在海外，美迪西客户覆盖美国、欧洲、日本、韩国等地区，已积累众多国际知名医药企业及科研机构客户，包括合作超过15年的武田制药、强生制药、葛兰素史克、罗氏制药、吉利德科学、诺华制药、默克制药、阿斯利康、礼来等，获多个著名医药企业奖项，如罗氏研发中国中心“最具价值合作伙伴奖”、美国Millennium公司“三年杰出合作伙伴奖”、美国Sunovion公司“优秀成果奖”、Sepracor公司“杰出研发奖”、Eluciderm“卓越服务奖”、RayThera“卓越合作伙伴奖”等。
合作从来双向成就。美迪西亦向 Revolution Medicines 颁发卓越客户奖，致敬其在pan-KRAS靶点领域的开创性探索，双方多年协同攻坚的里程碑成果。
行业之誉
以实力树立标杆，以专业引领发展
自2021年上市以来，美迪西持续斩获行业权威认可：公司七度蝉联药智网“中国CRO卓越品牌榜”20强，连续七年入选PDI大会“中国医药CRO企业20强”，同时上榜CMC-CHINA临床前CRO TOP25、FNS101未来医药新物种百强，获评年度客户最满意CRO，摘得药物创新济世奖年度十大药物创新服务机构、中国生物医药产业价值榜最具影响力CXO企业、中国医药研发50强、上海硬核科技企业TOP100、科创板硬科技领军企业、金牛科创奖等荣誉。
ESG建设方面，公司入选中国医药上市公司ESG竞争力TOP10，2026年Wind ESG评级提升至AA级，将ESG理念嵌入合规、质量、治理与研发全流程，夯实长期服务的底层根基。资本市场层面，斩获上市公司卓越投关建设奖、科创板硬科技投资价值奖。一系列荣誉，是公司坚持一站式临床前服务、全球化交付、高标准合规体系建设的必然成果。
平台之基
以技术筑牢根基，以平台赋能创新
荣誉背后，是持续沉淀的硬核平台能力。美迪西获评上海市高新技术企业、科技小巨人企业、专精特新企业、上海市市级企业技术中心、上海市创新型企业总部，拥有上海市研发公共服务平台、浦东新区企业研发机构、博士后工作站等资质。
公司子公司美迪西普亚建成多个市级专业技术服务平台：非人灵长类安全评价、同位素药物代谢研究、蛋白质晶体学药物筛选、核酸药物临床前研究平台，同步布局国际标准的安评、抗体药物研发、药代动力学、新型制剂、药效学评价等技术矩阵，持续承接前沿靶点、新型药物的研发挑战。
信赖植根同行，是一路并肩的回响；上市七载，感恩托付，共赴创新。
七年上市路，是时间刻度，更是成长坐标。每一份荣誉，都源于客户信任、合作伙伴支持、行业认可，以及全体美迪西人的坚守。创新不息，征途不止。美迪西将继续与各界同心携手，助力更多中国创新药走向全球。
关于美迪西
美迪西（股票代码：688202.SH）成立于 2004 年，专注于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研发服务。公司构建了覆盖药物发现、药学研究至临床前研究的一站式综合研发平台，并在 ADC/AOC、小核酸、多 (环) 肽、TPD、RIPTAC等前沿领域搭建了服务平台。公司建立了符合国际规范的质量体系，已获得中国 NMPA、美国 FDA、 OECD 等 GLP 认证以及 AAALAC 国际认证。目前，公司在上海和Boston拥有约 9.2 万平方米研发实验室。至 2026 年 6 月末，公司已为全球超 2000 家客户提供药物研发服务，参与研发完成的新药项目已有近700件IND临床批件。美迪西将继续携手国内外合作伙伴共同推动药物创新，为人类健康贡献力量。欢迎访问公司官网 www.medicilon.com.cn 了解更多详情。
7th Anniversary Q&A#7
Seven Years Listed, Honors Without Number: Why Does Medicilon Keep the Trust of the Industry and Its Clients?
Seven years after listing, Medicilon has kept building depth as innovative drug sector gathered pace. Over those seven years, the honors that have come its way — from the choices clients make to recognition from the industry, from technical breakthroughs to compliant delivery — are not isolated labels but long-term proof of one capability: one-stop preclinical service. At this seventh anniversary, why does the industry keep trusting Medicilon, and why do its clients stay?
Chosen by Clients
Trust Through Delivery
For a CRO, client trust is the highest commendation there is. Medicilon runs drug discovery, CMC, preclinical studies, and regulatory filing as one integrated preclinical service, giving global innovative drug companies stable, professional, and efficient support.
01
From Target to IND: One-Stop Delivery
The one-stop preclinical platform connects the whole chain from Target to IND: modules hand off without seams, data move between them, and the communication barriers and data gaps of coordinating several vendors disappear — while multi-country filings stay supported. To date, Medicilon has supported 43 complete IND packages to clinical approval.
They include Nanolattix Group 's ADC T320, filed and approved in China, the US, and Australia; Gluetacs Therapeutics's three degraders — GT919, GT929, and GT818 — each filed and approved in both China and the US; and Shanghai Yizhong Pharma's YXC-001 and YXC-002, whose approvals brought Medicilon's pharmaceutical and preclinical teams an Excellence in Partnership Award from the client. Biotime Biotechnology's BIOT-006, Wayne Biotech's WBD156, Yuyao Biotech's YY201 tablets, and HBOW Biotech's NC527-X have likewise been filed and approved in both China and the US on the Medicilon’s platform.
02
Holding the Dates: Ahead of Critical Milestones
Faced with tight timelines for new drug programs, the Medicilon team flexibly allocated manpower and resources, delivering milestones with exceptional execution. RayThera honored Medicilon team with its Outstanding Partner Award in recognition of our dedicated FTE team, who worked nonstop through holidays to shorten the timeline and deliver R&D ahead of schedule. ACEA Pharma sent a letter of commendation for the cross-departmental collaboration: during the emergency development of ormutrelvir sodium, a world-first dual-target oral COVID-19 drug, Medicilon advanced process scale-up, toxicology sample preparation and pharmacokinetic studies in parallel, securing precious time to accelerate the program.
03
Cracking the Hard Problems: Frontier Bottlenecks
Where frontier targets and new molecular modalities offer no mature reference protocol, the Medicilon’s teams redesign experiments themselves and build dedicated evaluation systems. Leadtac gave Medicilon’s DMPK team a special award for getting around the pain points of PROTAC molecules — large molecular weight, hard developability assessment. Immunophage gave Medicilon’s efficacy team a Best Partner Award for an MCAO modeling protocol that underpinned IPG7236, the first CCR small-molecule antagonist in the world to enter the clinic. Hexin Biotech gave Medicilon’s CMC team an Outstanding Partner Award for solving XY003's extremely low solubility and complex formulation. Tasly thanked the Medicilon’s team for a dedicated PBC evaluation system and high-standard efficacy work on TSL2402 tablets.
04
Global Collaboration: A Long-Term Community of Growth
Medicilon's relationships are moving from single-project delivery toward pipeline collaboration and long-term symbiosis. In China, it serves Hengrui Pharma, Yangtze River Pharmaceutical Group, Guangzhou Baiyunshan Pharmaceutical Holdings, Shanghai Pharmaceuticals, Livzon Pharmaceutical Group, China Resources Pharmaceutical Group, CSPC Pharmaceutical Group, and Huadong Medicine. Awards from clients include Jemincare's Outstanding Performance Award, Regor Therapeutics' Best Partner Award, ABM Therapeutics' Best Service Team Award, MindRank's Outstanding Team Award, SicaGene's Best Partner Award, Jingxin Pharmaceutical's Outstanding Contribution Team Award, and Gyre Pharmaceuticals' Toxicology Pioneer Award. The Hengrui relationship spans 15 years across small nucleic acids, antibodies, peptides, ADCs, and PROTACs. In ADC, Medicilon ran preclinical work for MediLink Therapeutics' YL201 and YL202 and contributed to payload R&D on the TMALIN platform, earning a Best Collaboration Award.
Globally, clients span the US, Europe, Japan, and Korea, among them Takeda (more than 15 years of partnership), Johnson & Johnson, GSK, Roche, Gilead Sciences, Novartis, Merck, AstraZeneca, and Lilly. Awards include Roche R&D Center China's Most Valuable Partner Award, Millennium's Three-Year Outstanding Partner Award, Sunovion's Outstanding Achievement Award, Sepracor's Excellence in R&D Award, and Eluciderm's Excellence in Service Award. RayThera's award appears above.
Partnership runs both ways: Medicilon gave Revolution Medicines an Outstanding Client Award for its pioneering pan-KRAS work and for what the two have reached together over years of joint effort.
Recognized by the Industry
Setting the Benchmark
Since listing, Medicilon has been named to Yaozh.com's China CRO Excellence Brand Top 20 for seven consecutive years and to the PDI Conference's China Pharmaceutical CRO Top 20 for seven consecutive years; it also appears in the CMC-CHINA Preclinical CRO Top 25 and the FNS101 Top 100 Future Pharma New Species. Among its titles: Most Satisfied CRO of the Year; Top 10 Innovative Drug Service Institutions at the Drug Innovation for Public Good Awards; Most Influential CXO on the China Biopharmaceutical Industry Value List; China Pharma R&D Top 50; Shanghai Hard-Tech Enterprise Top 100; STAR Market Hard-Tech Leader; and the Golden Bull STAR Award.
On ESG, the company ranks in the Top 10 for ESG Competitiveness among Chinese listed pharmaceutical companies, and its Wind ESG rating rose to AA in 2026, with ESG principles embedded in compliance, quality, governance, and R&D. In the capital markets it has won the Listed Company Excellence in Investor Relations Award and the STAR Market Hard-Tech Investment Value Award. These honors follow from the commitment to one-stop preclinical services, global delivery, and a high-standard compliance system.
Built on Platforms
Technology First
Behind the honors is platform capability built over years. Medicilon is recognized as a Shanghai High-Tech Enterprise, a Science and Technology Little Giant, a Specialized, Refined, Distinctive and Innovative enterprise, a Shanghai Municipal Enterprise Technology Center, and a Shanghai Innovative Enterprise Headquarters; it holds designations as a Shanghai R&D Public Service Platform, a Pudong New Area Enterprise R&D Institution, and a postdoctoral workstation.
Its subsidiary Medicilon Preclinical Research has built four municipal-level specialized platforms: non-human primate safety evaluation, isotope-labeled drug metabolism, protein crystallography-based drug screening, and nucleic acid drug preclinical research — and maintains an international-standard technology matrix across safety assessment, antibody R&D, pharmacokinetics, novel formulations, and pharmacodynamic evaluation, taking on the R&D challenges of frontier targets and novel drugs.
Trust takes root in a shared road; it is the echo of a journey made together.
Seven years listed — thank you for the confidence, and let us go further together. Every honor comes from client trust, from partners' support, from industry recognition, and from the commitment of everyone at Medicilon. Innovation does not rest, and Medicilon will keep joining hands across the industry to help more innovative drugs reach the world.
About Medicilon
Founded in 2004, Medicilon (Stock Code: 688202.SH) is dedicated to delivering comprehensive preclinical drug R&D services to pharmaceutical enterprises, research institutions, and scientific investigators worldwide. The company has established a one-stop integrated R&D platform encompassing drug discovery, pharmaceutical research, and preclinical research, and has developed service platforms in cutting-edge fields including ADC/AOC, RNAi, peptides (including macrocyclic peptides), TPD, and RIPTAC. The company has instituted a quality system compliant with international standards and has secured GLP certifications from China's NMPA, the U.S. FDA, and the EU's OECD, along with AAALAC International accreditation. At present, the company operates approximately 92,000 square meters of R&D laboratory space across Shanghai and Boston. As of the end of June 2026, the company has provided drug R&D services to over 2,000 clients globally and has supported nearly 700 IND approvals. For more information, visit www.medicilon.com.
评论 (0)